EA200000981A1 - Железо-декстрановое соединение для применения в качестве компонента терапевтической композиции для профилактики или лечения дефицита железа, способ получения указанного железо-декстранового соединения и применение указанного соединения для изготовления терапевтической композиции для парентерального введения - Google Patents

Железо-декстрановое соединение для применения в качестве компонента терапевтической композиции для профилактики или лечения дефицита железа, способ получения указанного железо-декстранового соединения и применение указанного соединения для изготовления терапевтической композиции для парентерального введения

Info

Publication number
EA200000981A1
EA200000981A1 EA200000981A EA200000981A EA200000981A1 EA 200000981 A1 EA200000981 A1 EA 200000981A1 EA 200000981 A EA200000981 A EA 200000981A EA 200000981 A EA200000981 A EA 200000981A EA 200000981 A1 EA200000981 A1 EA 200000981A1
Authority
EA
Eurasian Patent Office
Prior art keywords
daltons
dextran
iron
molecular weights
dalton
Prior art date
Application number
EA200000981A
Other languages
English (en)
Other versions
EA003427B1 (ru
Inventor
Ханс Берг Андреасен
Ларс Христенсен
Original Assignee
Фармакосмос Холдинг А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200000981(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармакосмос Холдинг А/С filed Critical Фармакосмос Холдинг А/С
Publication of EA200000981A1 publication Critical patent/EA200000981A1/ru
Publication of EA003427B1 publication Critical patent/EA003427B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Железо-декстрановое соединение для парентерального лечения железодефицитной анемии, содержащее гидрированный декстран со среднемассовой молекулярной массой (СМММ) от 700 до 1400 Дальтон, предпочтительно около 1000 Дальтон, среднечисловой молекулярной массой (СЧММ) от 400 до 1400 Дальтон, в котором 90 мас.% декстрана имеет молекулярные массы менее 2700 Дальтон, а СМММ 10 мас.% фракции декстрана, имеющего наивысшие молекулярные массы, составляет менее 3 200 Дальтон; указанный гидрированный декстран подвергается очистке с помощью мембранных процессов, имеющих отсекающую величину от 340 до 800 Дальтон, в стабильной ассоциации с оксигидроксидом железа. Это соединение изготавливают с помощью мембранных процессов для устранения декстранов с более высокими молекулярными массами, чем приблизительно 2700 Дальтон, и мембранных процессов для удаления сахаридов с молекулярными массами менее приблизительно 340 Дальтон из гидрированного декстрана перед осаждением гидроксида железа в присутствии указанного декстрана, после чего следует тепловая обработка и очистка.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000981A 1998-03-25 1999-03-24 Железо-декстрановое соединение для применения в качестве компонента терапевтической композиции для профилактики или лечения дефицита железа, способ получения указанного железо-декстранового соединения и применение указанного соединения для изготовления терапевтической композиции для парентерального введения EA003427B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199800420A DK172860B1 (da) 1998-03-25 1998-03-25 Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
PCT/DK1999/000160 WO1999048533A1 (en) 1998-03-25 1999-03-24 An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition

Publications (2)

Publication Number Publication Date
EA200000981A1 true EA200000981A1 (ru) 2001-02-26
EA003427B1 EA003427B1 (ru) 2003-04-24

Family

ID=8093321

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000981A EA003427B1 (ru) 1998-03-25 1999-03-24 Железо-декстрановое соединение для применения в качестве компонента терапевтической композиции для профилактики или лечения дефицита железа, способ получения указанного железо-декстранового соединения и применение указанного соединения для изготовления терапевтической композиции для парентерального введения

Country Status (28)

Country Link
US (1) US6291440B1 (ru)
EP (1) EP1066056B2 (ru)
JP (1) JP4558198B2 (ru)
KR (1) KR100612071B1 (ru)
CN (1) CN1147322C (ru)
AR (1) AR015738A1 (ru)
AT (1) ATE220560T1 (ru)
AU (1) AU740432B2 (ru)
BR (1) BRPI9908914B8 (ru)
CA (1) CA2322633C (ru)
CZ (1) CZ300823B6 (ru)
DE (1) DE69902154T3 (ru)
DK (2) DK172860B1 (ru)
EA (1) EA003427B1 (ru)
ES (1) ES2180279T5 (ru)
HK (1) HK1033426A1 (ru)
HU (1) HU228483B1 (ru)
ID (1) ID26778A (ru)
NO (1) NO329591B1 (ru)
NZ (1) NZ505983A (ru)
PL (1) PL195582B1 (ru)
PT (1) PT1066056E (ru)
SI (1) SI1066056T2 (ru)
SK (1) SK284499B6 (ru)
TR (1) TR200002733T2 (ru)
UA (1) UA70939C2 (ru)
WO (1) WO1999048533A1 (ru)
ZA (1) ZA200004016B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173138B1 (da) 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
DE60043188D1 (de) * 1999-04-09 2009-12-03 Amag Pharmaceuticals Inc Hitzebeständige umhüllte kolloidale eisenoxide
KR20020003344A (ko) * 2001-12-17 2002-01-12 유형선 철분 보급제 경구 투여 제제 조성물
BR0308773A (pt) * 2002-04-09 2005-02-09 Pharmacosmos Holding As Compostos de dextrina de ferro para tratamento de anemia por deficiência de ferro
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
ITMO20050056A1 (it) * 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
EP2626074A1 (en) 2006-01-06 2013-08-14 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP1947120A1 (de) * 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
EP1997833A1 (de) * 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
CN101585887B (zh) * 2008-05-22 2011-12-14 中国科学院过程工程研究所 应用纳滤技术对右旋糖酐铁络合物水溶液进行脱盐和浓缩的方法
EP3156075B1 (en) 2009-03-25 2020-10-14 Pharmacosmos Holding A/S An oligosaccharide and a process for preparation thereof
CN101967205B (zh) * 2010-10-12 2013-04-17 滨州学院 一种β-葡聚糖铁复合物及其制备方法
EP2537866A1 (en) 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
PL398814A1 (pl) 2012-04-16 2013-10-28 Uniwersytet Jagiellonski Zastosowanie pochodnych dekstranu do przeciwdzialania lub leczenia niedokrwistosci
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
HUE045092T2 (hu) * 2014-10-27 2019-12-30 Pharmacosmos Holding As Vérszegénység kezelése vagy megelõzése vemhes nem-humán emlõsökben és utódaikban
JP7426927B2 (ja) 2017-09-11 2024-02-02 ファーマコスモス ホールディング エー／エス 治療的使用のための鉄錯体化合
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药（苏州）股份有限公司 异麦芽糖酐铁1000的制备方法
CN110183548B (zh) * 2019-06-28 2021-05-18 瑞普（天津）生物药业有限公司 一种低分子葡聚糖铁的制备方法及其应用
BR112024002150A2 (pt) 2021-08-03 2024-04-30 Pharmacosmos Holding As Compostos de complexo de ferro para uso subcutâneo na terapia de deficiência de ferro em animais de companhia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24642E (en) 1959-04-28 Therapeutic preparations of iron
DK117730A (ru)
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3093545A (en) 1960-08-29 1963-06-11 Armour Pharma Therapeutic iron-dextran preparations
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
DE1293144B (de) * 1964-11-04 1969-04-24 Hausmann Ag Labor Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
GB1200902A (en) 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
CH507993A (de) 1967-07-13 1971-05-31 Kutnowskie Zakl Farma Verfahren zur Herstellung von Eisen(III)-komplexverbindungen mit hydriertem Dextran
DK129353B (da) 1968-04-29 1974-09-30 Fisons Pharmaceuticals Ltd Analogifremgangsmåde til fremstilling af et ferrihydroxid-dextranderivatkompleks eller en opløsning deraf.
US3697502A (en) 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
GB1562913A (en) * 1976-06-16 1980-03-19 Fisons Ltd Fractionating fluid mixtures of dextrans
DE3422249A1 (de) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
RU2093577C1 (ru) * 1993-11-04 1997-10-20 Государственный институт кровезаменителей и медицинских препаратов Способ получения декстрана
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US5624668A (en) * 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations

Also Published As

Publication number Publication date
BRPI9908914B1 (pt) 2012-06-12
NO20004151D0 (no) 2000-08-18
NO329591B1 (no) 2010-11-15
DE69902154D1 (de) 2002-08-22
BRPI9908914A (pt) 2000-11-21
US6291440B1 (en) 2001-09-18
SI1066056T2 (sl) 2009-04-30
ATE220560T1 (de) 2002-08-15
EA003427B1 (ru) 2003-04-24
DK1066056T4 (da) 2009-04-14
CA2322633A1 (en) 1999-09-30
UA70939C2 (ru) 2004-11-15
ES2180279T5 (es) 2009-05-05
EP1066056A1 (en) 2001-01-10
SI1066056T1 (en) 2002-12-31
NO20004151L (no) 2000-08-18
PL343164A1 (en) 2001-07-30
ES2180279T3 (es) 2003-02-01
DK172860B1 (da) 1999-08-16
SK14092000A3 (sk) 2001-04-09
CN1147322C (zh) 2004-04-28
DK1066056T3 (da) 2002-10-14
AU2827399A (en) 1999-10-18
KR100612071B1 (ko) 2006-08-11
EP1066056B2 (en) 2008-12-10
HK1033426A1 (en) 2001-08-31
CA2322633C (en) 2009-01-27
AR015738A1 (es) 2001-05-16
ID26778A (id) 2001-02-08
ZA200004016B (en) 2001-07-25
JP4558198B2 (ja) 2010-10-06
CN1293577A (zh) 2001-05-02
HUP0101189A2 (hu) 2001-08-28
SK284499B6 (sk) 2005-05-05
PT1066056E (pt) 2002-12-31
DK42099A (da) 1999-08-16
DE69902154T2 (de) 2003-03-06
NZ505983A (en) 2002-11-26
WO1999048533A1 (en) 1999-09-30
KR20010034641A (ko) 2001-04-25
CZ300823B6 (cs) 2009-08-19
JP2002507582A (ja) 2002-03-12
HUP0101189A3 (en) 2003-12-29
TR200002733T2 (tr) 2000-12-21
AU740432B2 (en) 2001-11-01
DE69902154T3 (de) 2009-07-09
EP1066056B1 (en) 2002-07-17
CZ20003535A3 (cs) 2001-04-11
PL195582B1 (pl) 2007-10-31
HU228483B1 (en) 2013-03-28
BRPI9908914B8 (pt) 2021-07-06

Similar Documents

Publication Publication Date Title
EA200000981A1 (ru) Железо-декстрановое соединение для применения в качестве компонента терапевтической композиции для профилактики или лечения дефицита железа, способ получения указанного железо-декстранового соединения и применение указанного соединения для изготовления терапевтической композиции для парентерального введения
NZ287335A (en) Copolymer-1 composition substantially free of species of copolymer -1 with a mw of from 4 kda to 8 kda, in particular 6.25 kda to 8.4 kda
SASAKI et al. Antitumor activity of degraded products of lentinan: its correlation with molecular weight
FI900446A0 (fi) Menetelmä uusien hepariinijohdannaisten valmistamiseksi
HK1094697A1 (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
RU95105023A (ru) Ароматические сополиамиды, способ их получения, формованное изделие и способ его получения
FR2387243A1 (fr) Procede pour purifier des extraits microbiens contenant des enzymes
CA2167749A1 (en) Polymeric dithiocarbamic acid salt compositions and methods of use
EA200401330A1 (ru) Железосодержащие соединения декстрина для лечения железодефицитной анемии
DE60231235D1 (de) Filter für die selektive eliminierung von leukozyten
FR2663940B1 (fr) Polysaccharides greffes, leur procede de preparation et leur application comme agents de sequestration.
DE69910079D1 (de) Behandlung von kalk
ES2026314A6 (es) Procedimiento para obtener una composicion profilactica antimicrobiana oftalmica neonatal.
CN106967182A (zh) 一种精氨酸固载壳聚糖的方法
BR9814595A (pt) "processo para reduzir o nìvel de aox de resinas de resistência em condições molhadas por tratamento com base"
DE3878577T2 (de) Verwendung von funktionellen polymerharzen als stationaere phase in der affinitaetschromatographie fuer die reinigung des wachstumsfaktors und entsprechendes reinigungsverfahren.
SE8504178L (sv) Mineralavvattningsmetod
KR890008206A (ko) 폴리아미노비스 이미드 계수지
FR2665163B1 (fr) Procede pour la preparation d'heparines calciques.
FR2659351B1 (fr) Compose polysaccharidique delipide, procede de preparation, compositions en comprenant.
GB1436466A (en) Method of treating drinks using powdered polyamide adsorbents
PT83868A (en) Process for preparing alpha-hydroxy thioethers
ATE127104T1 (de) Dithiocarbamat-gruppen enthaltende polymere.
CA2023721A1 (en) Copolymers containing amino groups and a process for their production
CA2151695A1 (fr) Procede de separation de diacides aliphatiques a partir de leurs melanges avec l'acide adipique

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM